PTK2B promotes tumorigenesis, migration, and invasion by activating several signaling pathways, including Wnt/β-catenin, PI3K/Akt, MAPK/ERK, and TGF-β/EGFR/VEGF, making it a promising target for cancer therapy [48, 49]. Here, EGFR is linked to cancer.